Objective: To describe the practical management of foslevodopa/foscarbidopa (LDp/CDp) for treating advanced Parkinson’s disease (aPD) in routine clinical practice using data collected through a patient support program.
Background: As Parkinson´s disease progresses to an advanced stage, many people with Parkinson’s (PwP) experience inadequate symptom control with levodopa-induced motor complications despite complex medication regimens. For these PwP, LDp/CDp, a continuous 24-hour subcutaneous infusion of levodopa and carbidopa prodrugs, has become available in many countries. LDp/CDp has demonstrated efficacy and safety in clinical trials, with local infusion site reactions common but predominantly non-serious and manageable. There is limited real-world data on practical experience with and implementation of LDp/CDp. The AbbVie Patient Support Program (PSP) for this therapy will educate PwP and their caregivers on the practicalities of using LDp/CDp, help with troubleshooting, and generate data to optimize support further.
Method: The Observational Retrospective CoHort study on Practical ExperienceS of Treatment with foslevodopa/foscaRbidopa in Advanced Parkinson’s Disease (ORCHESTRA study) will analyze data collected through the PSP via an AbbVie global platform, ONE-CRM, and describe the practical management of LDp/CDp in routine clinical practice, including initiation and optimization, infusion settings, possible complications, and support provided by the PSP. All analyses will be performed on de-identified and aggregated data adhering to the approved data collection plan and the General Data Protection Regulation.
Results: More than 2,000 PwP receiving LDp/CDp since its launch have been included across European participating countries. Data will be analyzed during 2025 and shared thereafter.
Conclusion: ONE-CRM used in the PSP will be a useful data source for the management of aPD in PwP treated with LDp/CDp, and help inform on practical experiences and real-world outcomes.
To cite this abstract in AMA style:
A. Johansson, E. Pekkonen, L. Dorresteijn, P. Schwingenschuh, J. Szász, L. Bergmann, M. O'Meara, J. Parra, M. Südmeyer. Design of ORCHESTRA Study: Practical Experiences With Foslevodopa/Foscarbidopa Treatment in Advanced Parkinson’s Disease [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/design-of-orchestra-study-practical-experiences-with-foslevodopa-foscarbidopa-treatment-in-advanced-parkinsons-disease/. Accessed October 5, 2025.« Back to 2025 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/design-of-orchestra-study-practical-experiences-with-foslevodopa-foscarbidopa-treatment-in-advanced-parkinsons-disease/